Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
CSPC Pharmaceutical Group Limited is a leading Chinese pharmaceutical company specializing in the research, development, manufacturing, and marketing of a wide range of drugs, particularly in oncology and cardiovascular treatments. The company benefits from a robust pipeline of innovative products and a strong distribution network across China, which positions it favorably within the competitive landscape.
CSPC generates revenue primarily through the sale of prescription pharmaceuticals, leveraging its strong R&D capabilities to introduce new drugs. The company enjoys pricing power due to its innovative product offerings and established market presence, particularly in oncology, where it has several leading products.
Approval and launch of new drugs, particularly in oncology
Changes in government healthcare policies affecting drug pricing
Market share fluctuations within the Chinese pharmaceutical sector
Foreign exchange rates impacting international sales
Regulatory changes affecting drug approval processes in China
Technological disruption in drug development and manufacturing
Intensifying competition from both domestic and international pharmaceutical companies
Potential for generic competition on key products
Low liquidity risk due to a strong current ratio of 2.19
Potential risks associated with R&D investments not yielding expected results
moderate - The pharmaceutical industry is somewhat insulated from economic cycles, but demand for non-essential drugs may decline during economic downturns.
CSPC's low debt levels (Debt/Equity of 0.02) minimize sensitivity to interest rate changes, but higher rates could impact consumer spending on healthcare products.
minimal - CSPC is not heavily reliant on credit markets due to its strong cash flow generation.
growth - CSPC's strong pipeline and market position may appeal to growth-oriented investors.
moderate - The stock has experienced significant volatility, with a 1-year return of -20.3%.
